For the quarter ending 2025-09-30, RVPHW had $2,819,545 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,010,773 | -12,486,450 |
| Change in fair value of warrant liabilities | 27,816 | -72,320 |
| Stock-based compensation expense | 458,379 | 1,314,396 |
| Prepaid clinical trial costs (current and non-current) | -22,705 | -436,154 |
| Prepaid expenses and other current assets | -99,037 | -319,471 |
| Accounts payable | 325,332 | -1,535,859 |
| Accrued expenses and other current liabilities | -2,511,982 | -1,182,338 |
| Net cash used in operating activities | -5,589,486 | -13,206,946 |
| Proceeds from issuance of short-term debt | 0 | 0 |
| Repayment of short-term debt | 113,246 | 344,908 |
| Proceeds from issuance of common stock in atm offering, net of transaction costs-The Market Offering Agreement Atm Agreement | 312,574 | 988,112 |
| Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of transaction costs | 8,209,703 | 9,210,000 |
| Proceeds from exercise of common stock warrants-Common Stock Warrants | 0 | 241,125 |
| Net cash provided by financing activities | 8,409,031 | 10,094,329 |
| Net decrease in cash and cash equivalents | 2,819,545 | -3,112,617 |
| Cash and cash equivalents at beginning of period | 13,476,331 | - |
| Cash and cash equivalents at end of period | 13,183,259 | - |
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)